Work

395P Afatinib in Asian and non-Asian patients (pts) with EGFR mutation positive (EGFRm+) NSCLC harboring major uncommon mutations

Year: 2020

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2020.10.389

Authors: J.C-H. Yang, M. Schuler, S. Popat, S. Miura, S. Heeke, A. Passaro, F. de Marinis, K. Park, E.S. Kim

Institutions: National Taiwan University Hospital, Essen University Hospital, Deutsches Konsortium für Translationale Krebsforschung, National Health Service, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Niigata Cancer Center Hospital, The University of Texas MD Anderson Cancer Center, European Institute of Oncology, Samsung Medical Center, Sungkyunkwan University, Levine Cancer Institute

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Celgene, Incyte, Yuhan, Ono Pharmaceutical, Genentech, Takeda Oncology

OpenAlex ID: W4231236372

FWCI: 0.141

Cites:

Cited by: 1

Related to: 10